Home » Topics » Science » New compound

New compound
RSS

HA-344 shows promise for treating cutaneous metastatic melanoma

Sep. 10, 2021

Novel virulence factor LasB inhibitors for the treatment of P. aeruginosa infections

Sep. 10, 2021

Discovery of novel antibiotic class of tethered macrocyclic peptides

Sep. 10, 2021

NIH develops PET radioligands targeting CSF-1R for neuroinflammation

Sep. 9, 2021

GABA-A alpha5 PAM RO-7015738 presented for neurological disorders

Sep. 9, 2021

[44Sc]Sc-B28110 shows preclinical promise as a radiotracer for the imaging of prostate cancer

Sep. 8, 2021

Discovery of novel new anti-cryptosporidial lead, SLU-2633

Sep. 7, 2021

IRF5 inhibition suppresses lupus-like disease in mice

Sep. 6, 2021

HEC-866, a novel pirfenidone analogue with improved therapeutic efficacy in models of IPF

Sep. 6, 2021

QGC-606 prevents LV dysfunction in mice post-MI

Sep. 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...